Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VT Tri allogeneic cell therapy - ViGenCell

Next Previous
Drug Profile

VT Tri allogeneic cell therapy - ViGenCell

Alternative Names: VT-Tri; VT-Tri (Allo); VT-Tri(1)-A; VT-Tri-A; VT-Tri-L

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViGenCell
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia
  • Discontinued Lung cancer

Most Recent Events

  • 28 May 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in South Korea (IV, Infusion)
  • 27 Apr 2020 Discontinued for Lung cancer in South Korea (IV) (ViGenCell pipeline, April 2020)
  • 27 Apr 2020 Phase-I clinical trials in Acute myeloid leukaemia in South Korea (IV) (ViGenCell pipeline, April 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top